

## PROVINCIAL FUNDING SUMMARY

### Lenalidomide (Revlimid) for Multiple Myeloma, Newly Diagnosed

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: December 18, 2015

This information is current as of May 10, 2017.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	April 1, 2017	<p>Patients with newly diagnosed multiple myeloma as per the updated International Myeloma Working Group criteria, who are ineligible for stem cell transplant</p> <ul style="list-style-type: none"> <li>• Life expectancy of greater than 3 months</li> <li>• Patients with renal impairment not on dialysis</li> <li>• A BC Cancer Agency "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment</li> <li>• Registration of the prescribing physician and patient with the RevAid Program (<a href="http://www.RevAid.ca">www.RevAid.ca</a>)</li> </ul>
AB	Funded	Oct 18, 2016	<p>As an option for first line treatment in patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment should be in combination with dexamethasone for patients with ECOG PS Less than or equal to 2 and until disease progression.</p>
SK	Funded	Oct 27, 2016	<p>As an option for first line treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment is in combination with dexamethasone for patients with an ECOG performance status of less than or equal than 2 and continued until disease progression.</p>
MB	Funded	Apr 20, 2017	<p>As an option for first line treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation (TNE). Treatment should be in combination with dexamethasone for patients with an ECOG performance status less than or equal to 2 and until disease progression.</p>

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	Mar 14, 2017	For first line treatment of patients with multiple myeloma who are not candidates for autologous stem cell transplantation. Treatment should be in combination with dexamethasone.
NS	Funded	Dec 1, 2016	As a first-line treatment option for newly diagnosed patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment should be in combination with dexamethasone for patients with ECOG performance status 0-2, and until disease progression.
NB	Funded	Dec 21, 2016	For the treatment of multiple myeloma, in combination with dexamethasone, in patients who are not candidates for autologous stem cell transplant and have: <ul style="list-style-type: none"> <li>• had no prior treatment,</li> <li>and • an ECOG performance status of <math>\leq 2</math>.</li> </ul> Treatment should be discontinued upon disease progression or unacceptable toxicity.
NL	Funded	Dec 31, 2016	For first line treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation (TNE). Treatment should be in combination with dexamethasone for patients with an ECOG performance status less than or equal to 2 and until disease progression.
PEI	Under Provincial Consideration		

*Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.*